Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Establishing Evidence Based Application of AN69-oXiris and PMX-HP Therapies Based on the Endotoxin Activity Assay in Septic Patients

NCT07788144 is registered in ClinicalTrials.gov with Kyoung Moo Im as lead sponsor.

NCT NCT07788144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07788144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Establishing Evidence Based Application of AN69-oXiris and PMX-HP Therapies Based on the Endotoxin Activity Assay in Septic Patients
Lead sponsor
Kyoung Moo Im
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
August 11, 2026
Completion date
December 31, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endotoxin levels, hemoperfusion, icu, sepsis